SEC EDGARAUG 271 min read$GILD

WELTERS ANTHONY sold $2.7M of GILD

WELTERS ANTHONY sold 18,000 shares of GILEAD SCIENCES, INC. (GILD) at an average of $148.62 ($148.24–$148.82, $2.68M total) across 4 trades on 2026-08-26 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · WELTERS ANTHONY

Published Aug 27, 2026, 10:44 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 27, 2026, 11:30 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$GILD

Bearish

medium confidence

Mentioned

$GILD

Relevance

5/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$GILDBearishLow

Why it matters

The disclosed sale reduces the director's ownership, which may be interpreted by investors as a slight bearish cue.

Market read

While the transaction is material for the insider, its effect on GILD's stock is likely modest.

What to watch

Potential upcoming catalyst (e.g., trial data) may offset the negative signal from the insider sale.

Relevance 5/10Novelty 5/10Timing: post‑market 2026‑08‑26

Background

Form 4 filings disclose insider transactions; director sales are monitored for potential signals.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$GILDBearishMedium confidence

Context

Director Anthony Welters sold 18,000 shares for $2.68M via a 10b5‑1 plan, reducing his stake to 12,894 shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

A director's $2.7M sale is sizable but not extraordinary; market may view it as a neutral to slightly negative signal.

Market effects

Sector

Minimal impact on the broader biotech/pharma sector.

Regional

Limited to U.S. markets where GILD trades.

Global

Low

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

Company
Gilead Sciences, Inc.
Biopharmaceutical company listed on NASDAQ.
Insider
Anthony Welters
Director of Gilead Sciences.

Read at source ← All news

SEP 5

$GILDHighAI 8/10

Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?

Gilead Sciences (GILD) received three FDA approvals in four months, boosting its stock 21% YTD. Recent approvals include Bixlenvo for HIV and Trodelvy for breast cancer. The company expects more approvals, including anito-cel for multiple myeloma by year-end. Gilead's Q2 revenue was $7.6B, up 8% YoY, with strong HIV drug sales. The company raised its dividend to $0.82, yielding 2.15%.

yahoo.com3 min

SEP 3

$GILDHighAI 8/10

Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?

Gilead Sciences (GILD) shares rose 13.6% since its last earnings report. Q2 2026 saw a narrower adjusted loss of $6.75 per share and revenue growth of 10% to $7.80 billion, driven by HIV portfolio and Trodelvy. GILD raised full-year HIV sales growth guidance to 9-10%.

finance.yahoo.com3 min

SEP 2

$MRKLowAI 8/10

Once-Weekly Oral Combination HIV Pill Shows Promise As Alternative to Daily Treatment

Merck and Gilead Sciences are developing a weekly oral HIV treatment combining islatravir and lenacapavir, both FDA-approved separately. The combination aims to offer an alternative to daily HIV medication.

healthandme.com1 min

SEP 2

$GILDHighAI 9/10

Tablet Regimen for Virologically Suppressed Adults Living with HIV

The FDA approved Gilead Sciences' Bixlenvo, a once-daily single-tablet HIV treatment for virologically suppressed adults. The drug combines bictegravir and lenacapavir, simplifying therapy and reducing pill burden. Clinical trials showed non-inferior viral suppression rates and improved health metrics. Bixlenvo is designed for patients with complex treatment histories or resistance challenges.

geneonline.com2 min

AUG 31

$GILDHighAI 9/10

A new once-daily pill to treat HIV just got the FDA’s green light

The FDA approved Gilead Sciences' once-daily HIV pill, Bixlenvo, for adults with suppressed HIV who cannot use current single-pill treatments. It combines bictegravir and lenacapavir, with a list price of $4,595 per month. Gilead aims to provide more treatment options, especially for older patients with complex regimens. According to the company, this group represents about 5% of HIV patients in the U.S.

advocate.com2 min